Effect of oXiris Hemofilter Use in Septic Shock: A Multicenter Retrospective Cohort Study

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age19+
SponsorSeoul National University Bundang Hospital

About this trial

This study aims to evaluate the clinical effectiveness of the oXiris® hemofilter in patients with septic shock and acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT). While some studies suggest that oXiris® may improve hemodynamic stability by removing endotoxins and cytokines, its impact on survival remains inconsistent.To provide more reliable causal evidence, this multicenter retrospective cohort study utilizes a Target Trial Emulation (TTE) approach. The study will compare patients treated with the oXiris® filter to those treated with standard CRRT filters, focusing on in-hospital mortality and other clinical outcomes such as fluid balance and vasopressor requirements.

Eligibility criteria

Qualifiers

Adults aged 19 years or older.

Admitted to the ICU with septic shock (Sepsis-3 criteria) between March 2021 and August 2025.

Required Continuous Renal Replacement Therapy (CRRT) due to acute kidney injury (AKI).

Disqualifiers

Death or withdrawal of life-sustaining therapy within 48 hours of ICU admission.

Patients with End-Stage Renal Disease (ESRD).

Patients with missing critical covariates.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

360 Participants
are grouped into 2 trial groups

Sponsors and collaborators